Since its inception in 2019, Emollivet has held a license for Lipidor’s IP relating to the animal segment and a royalty agreement has regulated
On
The purchase price has been set on market terms and amounts to
© Modular Finance, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.225 SEK | +2.27% | -3.02% | -55.36% |
22/04 | Lipidor AB Postpones the Publication of Annual Report for 2023 | CI |
21/03 | Lipidor AB Announces Approval for Start of Phase III Clinical Trial of Psoriasis Candidate AKP02G2 | CI |
Since its inception in 2019, Emollivet has held a license for Lipidor’s IP relating to the animal segment and a royalty agreement has regulated
On
The purchase price has been set on market terms and amounts to
© Modular Finance, source
1st Jan change | Capi. | |
---|---|---|
-55.36% | 6L | |
+29.82% | 68TCr | |
+30.35% | 59TCr | |
-3.74% | 36TCr | |
+17.49% | 33TCr | |
+3.52% | 28TCr | |
+15.53% | 24TCr | |
+10.16% | 21TCr | |
-8.14% | 20TCr | |
+7.34% | 17TCr |